ID   EFM-192B
AC   CVCL_1813
SY   EFM192B
DR   CLO; CLO_0002890
DR   EFO; EFO_0006569
DR   ArrayExpress; E-MTAB-2706
DR   Cell_Model_Passport; SIDM01054
DR   DSMZ; ACC-308
DR   DSMZCellDive; ACC-308
DR   EGA; EGAS00001000610
DR   GEO; GSM1172951
DR   GEO; GSM1172859
DR   LINCS_HMS; 51115
DR   LINCS_LDP; LCL-1312
DR   PharmacoDB; EFM192B_323_2019
DR   Wikidata; Q54832053
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28196595;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~4-5 days (DSMZ=ACC-308); 68.47 hours (GrayJW panel).
CC   HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03; DQB1*06:02,02:02; DRB1*15:01,09:10 (PubMed=25960936).
CC   HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 9,14
ST   D16S539: 8,13
ST   D18S51: 17
ST   D19S433: 14
ST   D21S11: 32.2
ST   D2S1338: 17,25
ST   D3S1358: 14,16
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 10
ST   FGA: 20,22
ST   Penta D: 9
ST   Penta E: 14,16
ST   TH01: 7
ST   TPOX: 8,10
ST   vWA: 16
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1812 ! EFM-192A
OI   CVCL_1814 ! EFM-192C
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 26
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//